



2024 CIBMTR Report of Survival Statistics for Blood and Marrow Transplants

September 12, 2025

Contents

Abbreviations	4
Introduction	5
Results	6
References	80

Tables

Table 1 Patients aged ≤ 18 , autoHCT for NHL during July 2010-June 2022	7
Table 2 Patients aged >18 , autoHCT for NHL during July 2010-June 2022	8
Table 3 Patients aged ≤ 18 , autoHCT for HL during July 2010-June 2022, by remission status	10
Table 4 Patients aged >18 , autoHCT for HL during July 2010-June 2022, by remission status	11
Table 5 Patients aged ≤ 18 , autoHCT for AML during July 2010-June 2022, by remission status	13
Table 6 Patients aged >18 , autoHCT for AML during July 2010-June 2022, by remission status	14
Table 7 Patients aged ≤ 18 , autoHCT ALL during July 2010-June 2022, by remission status	15
Table 8 Patients aged >18 , autoHCT for ALL during July 2010-June 2022, by remission status	16
Table 9 Patients of all ages, autoHCT for MM during July 2010-June 2022	17
Table 10 Patients of all ages, autoHCT for neuroblastoma during July 2010-June 2022	18
Table 11 Patients of all ages, autoHCT for testicular cancer during July 2010-June 2022	19
Table 12 Patients aged ≤ 18 , autoHCT for CNS (except CNS lymphoma and neuroblastoma) during July 2010-June 2022	20
Table 13 Patients aged >18 , autoHCT for CNS tumors (except CNS lymphoma and neuroblastoma) during July 2010-June 2022	21
Table 14 Patients of all ages, HLA-identical sibling HCT for CML during July 2010-June 2022, by disease phase	22
Table 15 Patients of all ages, HCT other than HLA-identical sibling for CML during July 2010-June 2022, by disease phase	24
Table 16 Patients aged ≤ 18 , HLA-identical sibling HCT for AML during July 2010 and June 2022, by disease status	27
Table 17 Patients aged >18 , HLA-identical sibling HCT for AML during July 2010-June 2022, by remission status	29
Table 18 Patients aged ≤ 18 , from donors other than HLA-identical sibling for AML during July 2010-June 2022, by remission status	31
Table 19 Patients aged >18 , HCT from donors other than HLA-identical sibling for AML during July 2010-June 2022, by remission status	34
Table 20 Patients aged ≤ 18 , HLA-identical sibling HCT for ALL during July 2010-June 2022, by remission status	37

Table 21 Patients aged >18, HLA-identical sibling HCT for ALL during July 2010-June 2022, by remission status.....	39
Table 22 Patients aged ≤ 18, HCT from donors other than HLA-identical siblings for ALL during July 2010-June 2022, by remission status	41
Table 23 Patients aged >18, HCT from donors other than HLA-identical siblings for ALL during July 2010-June 2022, by remission status	43
Table 24 Patients of all ages, HLA-identical sibling HCTs for MDS during July 2010-June 2022, by disease stage.....	46
Table 25 Patients of all ages, HCT from donors other than HLA-identical siblings for MDS during July 2010-June 2022, by disease stage	48
Table 26 Patients of all ages, HLA-identical sibling HCT for NHL during July 2010-June 2022, by disease subtype	50
Table 27 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for non-Hodgkin lymphoma during July 2010-June 2022, by disease stage	54
Table 28 Characteristics of patients receiving allogeneic transplants for Hodgkin lymphoma during July 2010-June 2022, by donor type	58
Table 29 Characteristics of patients receiving HLA-identical sibling transplants for multiple myeloma during July 2010-June 2022, by time from DX to HCT	61
Table 30 Characteristics of patients receiving transplants from donors other than HLA-identical siblings for multiple myeloma during July 2010-June 2022, by time from DX to HCT	63
Table 31 Characteristics of patients ≤ 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2010-June 2022, by donor type.....	65
Table 32 Characteristics of patients > 18 years of age receiving allogeneic transplants for severe aplastic anemia during July 2010-June 2022, by donor type.....	68
Table 33 Characteristics of patients receiving allogeneic transplants for Fanconi anemia during July 2010-June 2022, by donor type	71
Table 34 Characteristics of patients receiving allogeneic transplants for thalassemia between July 2010-June 2022, by donor type	73
Table 35 Characteristics of patients receiving allogeneic transplants for SCID during July 2010-June 2022, by donor type.....	75
Table 36 Characteristics of patients receiving allogeneic transplants for inherited disorders during July 2010-June 2022, by donor type	77

Abbreviations

Abbreviation	Expansion
ALL	acute lymphoblastic leukemia
alloHCT	allogeneic hematopoietic cell transplantation
AML	acute myeloid leukemia
autoHCT	autologous hematopoietic cell transplantation
BEAM	BCNU [carmustine], etoposide, Ara-C [cytarabine], and melphalan
Bu	busulfan
Carb	carboplatin
CBV	cyclophosphamide, BCNU [carmustine], and VP-16 [etoposide]
CML	chronic myeloid leukemia
CNI	calcineurin inhibitor
CNS	central nervous system
CR	complete remission
CR \geq 2	second or greater complete remission
CR1	first complete remission
Cy	cyclophosphamide
Dx	diagnosis
Etop	etoposide
FA	Fanconi anemia
FCR	fludarabine, cyclophosphamide and rituximab
Flu	fludarabine
GVHD	graft-versus-host disease
HCT	hematopoietic cell transplantation
HL	Hodgkin lymphoma
HLA	human leukocyte antigen
MDS	myelodysplastic syndrome
Mel	melphalan
MM	multiple myeloma
MMF	mycophenolate mofetil
MTX	methotrexate
NE	not evaluable
NHL	non-Hodgkin lymphoma
NMA	non-myeloablative
PR	partial remission
PTCy	post-transplant cyclophosphamide
RIC	reduced-intensity conditioning
SAA	severe aplastic anemia
SCID	severe combined immunodeficiency
TBI	total body irradiation
TLI	total lymphoid irradiation
TT	thiotepa
VP	etoposide

Introduction

The following tables describe the use and outcome of autologous and allogeneic blood and bone marrow transplants in the more than 350 centers participating in CIBMTR® (Center for International Blood and Marrow Transplant Research®). Prior to 2007, we estimate CIBMTR captured 90% of all unrelated donor transplants performed in the US, 60-90% of related donor allogeneic transplants, and 65-75% of autologous transplants. After 2007, CIBMTR collects data on all allogeneic transplants performed in the US and 80% of autologous transplants.

Table 1-13 (autologous) and Tables 14-36 (allogeneic) show patient characteristics and probabilities of survival ($\pm 95\%$ CIs) post-transplant at 100 days, and at 1, 3 and 5 years. Categorical variables are represented by N (%), continuous variables by median (range). Probabilities were calculated using the Kaplan-Meier estimator. Some groups lack sufficient data for calculation of probabilities beyond 2-3 years. These are indicated by footnotes which give the time of the last censored observation. Outcomes were stratified on disease and disease state pre-transplant. However, it should be remembered that these groups are still heterogeneous with regard to age, prior treatment, chemotherapy-sensitivity and other important prognostic factors. Extrapolating to individual patients or centers may not be appropriate.

The enclosed raw data represents a preliminary review of information registered to CIBMTR. The analysis has not been reviewed or approved by the Advisory or Scientific Committee of CIBMTR.

PLEASE NOTE: The enclosed data are for your own information and may be used in oral, but not written presentations. Unauthorized reproduction is prohibited.

Please contact CIBMTR for information on obtaining written permission to reproduce the enclosed data.

Data source

the Medical College of Wisconsin and NMDP. CIBMTR collaborates with scientists around the globe to study cellular therapies and cure life-threatening diseases, many of which are rare.

More than 310 medical centers worldwide submit clinical data to CIBMTR about hematopoietic cell transplantation and other cellular therapies, such as chimeric antigen receptor T cells (CAR-Ts). These therapies treat malignant and non-malignant hematologic conditions and some other disorders. By analyzing these data, CIBMTR identifies the best treatments to help people live longer and enjoy better quality of life.

CIBMTR also collects and analyzes participant-reported outcomes and quality of life data.

CIBMTR maintains one of the world's largest observational databases of clinical information on HCT and other cellular therapies. Data are collected, stored, and shared under terms of the *Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries* and its accompanying consent forms.¹⁻⁵ At the time of treatment, patients consent for their data to be entered into the Research Database and used to support a broad research agenda. Currently, CIBMTR's Research Database includes long-term clinical data from more than 700,000 patients.

The database includes:

- Almost 100% of allogeneic transplants in the US
- More than 85% of autologous transplants in the US
- About 27,500 patients who received other cellular therapies

CIBMTR holds the contract for the Stem Cell Therapeutic Outcomes Database, awarded by the Health Resources and Services Administration of the US Department of Health and Human Services. As the contract holder, CIBMTR is charged with collecting data on all allogeneic (related and unrelated) hematopoietic cell transplantations performed in the US. All US transplant centers are required to report data to CIBMTR; participation of non-US centers is voluntary.

CIBMTR also maintains a biorepository with tissue samples.⁵ CIBMTR's unique staff of physicians, biostatisticians, research coordinators, data management staff and IT teams conduct both observational research and clinical trials.

Transplant data

CIBMTR collects transplant data on 2 levels: Transplant Essential Data (TED) and Comprehensive Report Form (CRF). CIBMTR collects TED data on all patients. TED data are an internationally accepted standard data set that includes hundreds of details about patients' demographics, disease, treatment, response, side effects, and long-term outcomes. Using a regularly reviewed, weighted algorithm, CIBMTR selects a subset of patients for more detailed CRF data collection.

Approximately 75% of CIBMTR centers provide CRF data; this accounts for more than 25% of cases submitted to CIBMTR annually.

TED and CRF data are collected pre-transplant, 100 days post-transplant, 6 months post-transplant, annually until year 6 post-transplant, and biannually thereafter until death or lost to follow-up.

Data quality

CIBMTR subjects data to a series of automated and manual quality checks. CIBMTR data operations teams work directly with centers to maintain both consistency and quality of data collected. In addition, CIBMTR performs on-site source data audits, and each member center is audited within a 4-year cycle. These validations and verifications produce high-quality data. If a center fails to meet data quality standards, its data are removed (embargoed) from research studies.

Ethics

CIBMTR protects the privacy and human rights of participants.⁶ CIBMTR obeys international laws and ethical guidelines, including the United States Health Insurance Portability and Accountability Act (HIPAA) and the European Union's General Data Protection Regulation (GDPR). The NMDP Institutional Review Board, which is fully accredited by the Association for the Accreditation of Human Research Protection Programs, reviews CIBMTR's research. Patients and/or guardian(s) give informed consent for research.

Results

Note: The enclosed data are confidential and represent a preliminary review of information submitted to the CIBMTR. The analysis has not been reviewed or approved by the Statistical or Scientific Committees of the CIBMTR. The data may not be published without prior approval of the CIBMTR.